Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELISPOT-guided prediction of cytomegalovirus infection after kidney transplantation
2013-004445-17Phase 4Active
- Sponsor
- Bellvitge University Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of valganciclovir and ganciclovir in cytomegalovirus disease (CMV) (4 arms), sponsored by Bellvitge University Hospital. Started Jan 2014; status: active.
02
Drugs
valganciclovirganciclovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-004445-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004445-17.